PRPO
Precipio
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 0
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About PRPO
Precipio, Inc.
A healthcare company focused on cancer diagnostics
Life Science Tools and Services
03/06/1997
06/30/2017
NASDAQ Stock Exchange
54
12-31
Common stock
4 Science Park, New Haven, CT 06511
--
Precipio, Inc., was incorporated in Delaware on March 6, 1997. GMO, the company is a global advance in personalized medicine in the detection of cancer and the treatment of hereditary diseases through its proprietary molecular technology and world-class clinical and scientific research services. The organization and review of GMO's business is presented by two complementary business units managed along its product line and below; genetic analysis platform and laboratory services.
Company Financials
EPS
PRPO has released its 2023 Q3 earnings. EPS was reported at -1.04, versus the expected -1.21, beating expectations. The chart below visualizes how PRPO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PRPO has released its 2024 Q4 earnings report, with revenue of 5.45M, reflecting a YoY change of 25.90%, and net profit of -365.00K, showing a YoY change of -139.46%. The Sankey diagram below clearly presents PRPO’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
